A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

National Taiwan University Hospital /ID# 164000, Taipei

National Cheng Kung University Hospital /ID# 164002, Tainan City

Taipei Medical University Hospital /ID# 164001, Taipei

AP-HM - Hopital de la Timone /ID# 165036, Marseille

Virginia Cancer Specialists - Fairfax /ID# 160787, Fairfax

University of Virginia /ID# 212895, Charlottesville

Hospital General Universitario Gregorio Maranon /ID# 205999, Madrid

CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 205996, Madrid

Hospital Universitario Fundacion Jimenez Diaz /ID# 211500, Madrid

Carolina BioOncology Institute /ID# 160786, Huntersville

Hospital Universitario Puerta de Hierro, Majadahonda /ID# 206973, Majadahonda

Greenville Hospital System /ID# 160785, Greenville

CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 208879, Pamplona

Hospital Clinico Universitario de Valencia /ID# 211499, Valencia

Centre Leon Berard /ID# 165037, Lyon

Institut Curie /ID# 165038, Paris

South Texas Accelerated Research Therapeutics /ID# 160788, San Antonio

Moores Cancer Center at UC San Diego /ID# 201334, La Jolla

Stanford University /ID# 206949, Stanford

Institut Gustave Roussy /ID# 165035, Villejuif

University of California, Davis Comprehensive Cancer Center /ID# 201342, Sacramento

Yale University /ID# 207895, New Haven

University of Texas Southwestern Medical Center /ID# 201934, Dallas

National Cancer Center Hospital East /ID# 214530, Kashiwa-shi

National Cancer Center Hospital /ID# 214531, Chuo-ku

Pan American Center for Oncology Trials, LLC /ID# 213809, Rio Piedras

Hospital Duran i Reynals /ID# 205997, L'Hospitalet de Llobregat